{"entity":{"id":"2010","kind":"year","name":"2010 in oncology","aka":["2010"],"tldr":"Everything OnCo dates to 2010: 228 entries, 62 landmarks, 57 papers listed on people's pages, 50 papers and 15 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"228 dated entries in OnCo fall in 2010: 62 landmarks, 57 papers listed on people's pages, 50 papers, 15 trials reported, 14 approvals, 10 companies founded, 8 journals founded, 8 technologies, 2 laws and regulations and 2 regulatory events.\n\nOf those, 2 to the day and 226 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2009","2011"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2010,"events":[{"group":"approval","date":"2010","precision":"year","title":"Bendamustine approved in EU","note":"CLL, indolent NHL, multiple myeloma (national approvals)","from":"bendamustine","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Cabazitaxel approved in US","note":"mCRPC after docetaxel","from":"cabazitaxel","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Denosumab approved in US","note":"Prevention of skeletal-related events in bone metastases from solid tumours (Xgeva); postmenopausal osteoporosis and treatment-induced bone loss (Prolia)","from":"denosumab","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Eribulin approved in US","note":"Metastatic breast cancer after ≥2 regimens including an anthracycline and a taxane","from":"eribulin","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH) approved in US","note":"HER2 testing extended to gastric and GEJ adenocarcinoma with trastuzumab (ToGA)","from":"her2-testing-assays","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Hexaminolevulinate approved in US","note":"Cystoscopic detection of non-muscle-invasive papillary bladder cancer, with blue-light cystoscopy","from":"hexaminolevulinate","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Lapatinib approved in US","note":"HR+/HER2+ metastatic breast cancer with letrozole","from":"lapatinib","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Nilotinib approved in US","note":"Newly diagnosed Ph+ CML chronic phase","from":"nilotinib","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Ofatumumab approved in EU","note":"CLL refractory to fludarabine and alemtuzumab (conditional; authorisation since withdrawn)","from":"ofatumumab","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Rituximab approved in US","note":"CLL with fludarabine and cyclophosphamide","from":"rituximab","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Sipuleucel-T approved in US","note":"Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","from":"sipuleucel-t","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Thiotepa approved in EU","note":"Conditioning before haematopoietic progenitor cell transplantation for haematological diseases and solid tumours (Tepadina)","from":"thiotepa","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Tocilizumab approved in US","note":"Rheumatoid arthritis (first approval)","from":"tocilizumab","refs":[]},{"group":"approval","date":"2010","precision":"year","title":"Trastuzumab approved in US","note":"HER2+ gastric cancer","from":"trastuzumab","refs":[]},{"group":"company","date":"2010","precision":"year","title":"AbClon founded","note":"Seoul","from":"abclon","refs":[]},{"group":"company","date":"2010","precision":"year","title":"Blaze Bioscience founded","note":"Seattle, WA","from":"blaze-bioscience","refs":[]},{"group":"company","date":"2010","precision":"year","title":"Carthera founded","note":"Lyon","from":"carthera","refs":[]},{"group":"company","date":"2010","precision":"year","title":"Fondazione Italiana Linfomi founded","note":"Alessandria","from":"fondazione-italiana-linfomi","refs":[]},{"group":"company","date":"2010","precision":"year","title":"Longwood Fund founded","note":"Boston, MA","from":"longwood-fund","refs":[]},{"group":"company","date":"2010","precision":"year","title":"On Target Laboratories founded","note":"West Lafayette, IN","from":"on-target-laboratories","refs":[]},{"group":"company","date":"2010","precision":"year","title":"Rakuten Medical founded","note":"San Diego","from":"rakuten-medical","refs":[]},{"group":"company","date":"2010","precision":"year","title":"Sichuan Huiyu Pharmaceutical founded","note":"Neijiang, Sichuan","from":"sichuan-huiyu-pharmaceutical","refs":[]},{"group":"company","date":"2010","precision":"year","title":"Wuhan YZY Biopharma founded","note":"Wuhan","from":"wuhan-yzy-biopharma","refs":[]},{"group":"company","date":"2010","precision":"year","title":"WuXi Biologics founded","note":"Wuxi / Shanghai","from":"wuxi-biologics","refs":[]},{"group":"history","date":"2010","precision":"year","title":"A second line opens","note":"Prostate cancer. TROPIC gave cabazitaxel after docetaxel: 15.1 against 12.7 months, with grade 3 or higher neutropenia in 82 percent.","from":"prostate","refs":["paper-de-bono-tropic-cabazitaxel-lancet-2010"]},{"group":"history","date":"2010","precision":"year","title":"A3961: biology-based reduction to four or eight cycles gives 96 percent three-year survival","note":"Intermediate-risk neuroblastoma","from":"neuroblastoma-intermediate-risk","refs":["carboplatin","etoposide","cyclophosphamide","doxorubicin"]},{"group":"history","date":"2010","precision":"year","title":"ABC-02: gemcitabine plus cisplatin becomes the standard for advanced biliary cancer","note":"Intrahepatic cholangiocarcinoma","from":"intrahepatic-cholangiocarcinoma","refs":["abc-02","gemcitabine-cisplatin"]},{"group":"history","date":"2010","precision":"year","title":"ABC-02: gemcitabine plus cisplatin standard for advanced biliary cancer","note":"Extrahepatic cholangiocarcinoma (perihilar and distal)","from":"extrahepatic-cholangiocarcinoma","refs":["abc-02","gemcitabine-cisplatin"]},{"group":"history","date":"2010","precision":"year","title":"ABC-02: gemcitabine-cisplatin becomes standard","note":"Biliary tract cancer (cholangiocarcinoma)","from":"cholangiocarcinoma","refs":["abc-02","gemcitabine-cisplatin"]},{"group":"history","date":"2010","precision":"year","title":"ABC-02: gemcitabine-cisplatin becomes standard","note":"Biliary tract cancer (all types)","from":"biliary-tract-cancer","refs":["abc-02"]},{"group":"history","date":"2010","precision":"year","title":"AMC 034: rituximab with EPOCH is safe and effective","note":"HIV-associated (AIDS-related) lymphomas. Sparano and colleagues (Blood 2010) establish concurrent R-EPOCH.","from":"hiv-associated-lymphoma","refs":["rituximab","etoposide"]},{"group":"history","date":"2010","precision":"year","title":"ANBL0032: anti-GD2 antibody with GM-CSF and interleukin-2 raises two-year event-free survival from 46 to 66 percent","note":"High-risk neuroblastoma","from":"neuroblastoma-high-risk","refs":["anbl0032","dinutuximab"]},{"group":"history","date":"2010","precision":"year","title":"ANBL0032: anti-GD2 immunotherapy raises survival ~20 points (NEJM)","note":"Neuroblastoma (paediatric)","from":"neuroblastoma","refs":["anbl0032","dinutuximab"]},{"group":"history","date":"2010","precision":"year","title":"Ang shows HPV status is the dominant prognostic factor","note":"Oropharyngeal cancer (tonsil and base of tongue). RTOG 0129 analysis: three-year survival 82 versus 57 percent.","from":"oropharyngeal-cancer","refs":[]},{"group":"history","date":"2010","precision":"year","title":"Anti-GD2 (ch14.18) improves EFS","note":"Neuroblastoma (paediatric)","from":"neuroblastoma","refs":[]},{"group":"history","date":"2010","precision":"year","title":"ARID1A mutations discovered in clear cell carcinoma","note":"Clear cell ovarian cancer","from":"clear-cell-ovarian-cancer","refs":[]},{"group":"history","date":"2010","precision":"year","title":"BAP1 loss drives metastasis (Harbour, Science)","note":"Uveal melanoma","from":"uveal-melanoma","refs":[]},{"group":"history","date":"2010","precision":"year","title":"BET inhibitor JQ1 induces differentiation of NUT carcinoma cells","note":"NUT carcinoma (midline carcinoma with NUTM1 rearrangement). Filippakopoulos and colleagues, Nature: proof of concept for BET inhibition.","from":"nut-carcinoma","refs":[]},{"group":"history","date":"2010","precision":"year","title":"BRAF V600E discovered in Langerhans cell histiocytosis","note":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","from":"lch-multisystem","refs":["braf","ras-mapk"]},{"group":"history","date":"2010","precision":"year","title":"BRAF V600E discovered in LCH","note":"Langerhans cell histiocytosis (LCH). Badalian-Very and colleagues (Blood) show LCH is a clonal MAPK-driven neoplasm.","from":"langerhans-cell-histiocytosis","refs":["braf","ras-mapk"]},{"group":"history","date":"2010","precision":"year","title":"BRAF V600E found in over half of lesions","note":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","from":"lch-single-system","refs":["braf","ras-mapk"]},{"group":"history","date":"2010","precision":"year","title":"Cabazitaxel and sipuleucel-T approved","note":"Metastatic castration-resistant prostate cancer","from":"prostate-mcrpc","refs":["cabazitaxel","sipuleucel-t"]},{"group":"history","date":"2010","precision":"year","title":"Claudin-low described as a breast cancer subtype","note":"Triple-negative breast cancer (TNBC). Mostly triple-negative tumours with epithelial-to-mesenchymal transition and stem-cell features (Prat, Breast Cancer Research); re-defined as...","from":"tnbc","refs":["claudin-low"]},{"group":"history","date":"2010","precision":"year","title":"CLL8: fludarabine-cyclophosphamide-rituximab lengthens life, the first regimen to do so","note":"Chronic lymphocytic leukaemia, first treatment","from":"cll-treatment-naive","refs":["fludarabine","rituximab"]},{"group":"history","date":"2010","precision":"year","title":"Copy-number burden as a risk measure","note":"Prostate cancer. Profiling 218 tumours on three platforms identifies NCOA2 as an oncogene in 11% and shows that counting copy-number changes separates high- from low-risk disease b...","from":"prostate","refs":["paper-taylor-integrative-genomic-profiling-cancer-cell-2010","ncoa2"]},{"group":"history","date":"2010","precision":"year","title":"Crizotinib response in ALK-positive IMT","note":"Inflammatory myofibroblastic tumour (IMT). Butrynski and colleagues, NEJM case report.","from":"inflammatory-myofibroblastic-tumour","refs":[]},{"group":"history","date":"2010","precision":"year","title":"Cystic duct cancer joins gallbladder staging","note":"Gallbladder cancer. The AJCC 7th edition stages carcinoma of the cystic duct with gallbladder cancer.","from":"gallbladder","refs":["cystic-duct-carcinoma"]},{"group":"history","date":"2010","precision":"year","title":"Drug-eluting bead TACE (PRECISION V) matches conventional TACE with less toxicity","note":"Intermediate hepatocellular carcinoma (BCLC B)","from":"hcc-intermediate","refs":["tace"]},{"group":"history","date":"2010","precision":"year","title":"Early palliative care trial","note":"Metastatic cancer (cancer that has spread). Temel and colleagues randomise newly diagnosed metastatic lung cancer patients to early palliative care with standard oncology: better q...","from":"metastatic-cancer","refs":["palliative-care"]},{"group":"history","date":"2010","precision":"year","title":"Endoscopic endonasal resection shown equivalent to craniofacial resection in series","note":"Esthesioneuroblastoma (olfactory neuroblastoma)","from":"esthesioneuroblastoma","refs":[]},{"group":"history","date":"2010","precision":"year","title":"EORTC 62961: regional hyperthermia with chemotherapy improves survival in high-risk STS","note":"Sarcomas (soft tissue, bone, GIST)","from":"sarcoma","refs":["hyperthermia"]},{"group":"history","date":"2010","precision":"year","title":"FCR: first regimen to improve survival","note":"Chronic lymphocytic leukaemia. CLL8 shows fludarabine-cyclophosphamide-rituximab beats FC on OS; rituximab approved in CLL.","from":"cll","refs":["rituximab"]},{"group":"history","date":"2010","precision":"year","title":"Fusion-negative alveolar RMS behaves like embryonal (Williamson, JCO)","note":"Rhabdomyosarcoma. Leads to fusion-based risk stratification.","from":"rhabdomyosarcoma","refs":[]},{"group":"history","date":"2010","precision":"year","title":"G-PCNSL-SG-1: omitting WBRT does not shorten survival","note":"Primary CNS lymphoma. Sets the stage for radiation-free strategies.","from":"primary-cns-lymphoma","refs":[]},{"group":"history","date":"2010","precision":"year","title":"Gemcitabine and cisplatin become the biliary standard","note":"Gallbladder cancer. ABC-02 (NEJM 2010) in a mixed biliary population including gallbladder cancer.","from":"gallbladder","refs":["abc-02","gemcitabine-cisplatin"]},{"group":"history","date":"2010","precision":"year","title":"Gene-expression tissue-of-origin classifiers reach clinical use","note":"Cancer of unknown primary, favourable subsets","from":"cup-favourable-subsets","refs":[]},{"group":"history","date":"2010","precision":"year","title":"GHSG HD10: two ABVD and 20 Gy suffice for early favourable disease","note":"Early-stage classical Hodgkin lymphoma (stage I to II)","from":"early-stage-classical-hodgkin-lymphoma","refs":["abvd-beacopp","imrt-igrt"]},{"group":"history","date":"2010","precision":"year","title":"Intensity-modulated radiotherapy shown to reduce xerostomia and improve control","note":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","from":"locoregionally-advanced-nasopharyngeal-carcinoma","refs":["imrt-igrt"]},{"group":"history","date":"2010","precision":"year","title":"Ipilimumab is the first drug to extend survival in metastatic melanoma","note":"Melanoma. Hodi et al., NEJM.","from":"melanoma","refs":["ipilimumab"]},{"group":"history","date":"2010","precision":"year","title":"Ipilimumab is the first drug to lengthen survival in advanced melanoma","note":"Advanced melanoma (unresectable stage III and stage IV)","from":"advanced-melanoma","refs":["ipilimumab"]},{"group":"history","date":"2010","precision":"year","title":"ITMIG founded; global retrospective database","note":"Thymoma and thymic carcinoma","from":"thymic-epithelial","refs":[]},{"group":"history","date":"2010","precision":"year","title":"Johns Hopkins series: 10 percent of resected adenocarcinomas are IPMN-associated, five-year survival 42 against 19 percent","note":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","from":"ipmn-associated-carcinoma","refs":["whipple"]},{"group":"history","date":"2010","precision":"year","title":"Kuma Hospital reports safe observation of microcarcinomas","note":"Papillary thyroid cancer. Ito and Miyauchi's series of over a thousand patients.","from":"papillary-thyroid-cancer","refs":[]},{"group":"history","date":"2010","precision":"year","title":"Mammary analogue secretory carcinoma with ETV6-NTRK3 described (Skálová)","note":"Salivary gland cancers","from":"salivary-gland","refs":["ntrk"]},{"group":"history","date":"2010","precision":"year","title":"MD Anderson phase 2: neoadjuvant TIP produces responses in half of men with bulky nodes","note":"Node-positive and metastatic penile cancer","from":"node-positive-penile-cancer","refs":["paclitaxel","ifosfamide","cisplatin"]},{"group":"history","date":"2010","precision":"year","title":"Metastasis shown to occur late","note":"Pancreatic ductal adenocarcinoma. A decade from the initiating mutation to the founder clone and five more years to metastatic ability: the quantitative case for early detection.","from":"pancreatic","refs":["paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010"]},{"group":"history","date":"2010","precision":"year","title":"MYC amplification found in radiation-associated and lymphoedema angiosarcoma","note":"Angiosarcoma","from":"angiosarcoma","refs":[]},{"group":"history","date":"2010","precision":"year","title":"NSABP B-32: the sentinel node replaces axillary clearance","note":"Breast cancer (all types). 5,611 women; eight-year overall survival 90.3 against 91.8 percent, and in ALMANAC lymphoedema at a year fell from 13 to 5 percent.","from":"breast-cancer","refs":["nsabp-b32","almanac"]},{"group":"history","date":"2010","precision":"year","title":"One flexible sigmoidoscopy, and the adenoma detection rate","note":"Colorectal cancer. Atkin, 170,432 people: incidence down 23 percent and mortality 31 percent, still holding at 17 years.","from":"colorectal","refs":["paper-atkin-once-only-flexible-sigmoidoscopy-lancet-2010","paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017","paper-kaminski-adenoma-detection-rate-interval-cancer-nejm-2010"]},{"group":"history","date":"2010","precision":"year","title":"Pooled EORTC 62027 and SWOG S0345: imatinib responses in about half of patients (JCO)","note":"Dermatofibrosarcoma protuberans","from":"dermatofibrosarcoma-protuberans","refs":["imatinib"]},{"group":"history","date":"2010","precision":"year","title":"PORTEC-2: vaginal brachytherapy replaces pelvic radiation for intermediate risk","note":"Endometrial cancer","from":"endometrial","refs":["brachytherapy"]},{"group":"history","date":"2010","precision":"year","title":"PORTEC-2: vaginal brachytherapy replaces pelvic radiotherapy for high-intermediate risk","note":"Endometrial cancer with no specific molecular profile","from":"endometrial-nsmp","refs":["brachytherapy"]},{"group":"history","date":"2010","precision":"year","title":"RTOG 0129 analysis: HPV status is the strongest prognostic factor","note":"HPV-positive oropharyngeal cancer","from":"hpv-positive-oropharyngeal-cancer","refs":["rtog-0129"]},{"group":"history","date":"2010","precision":"year","title":"RTOG 0129: HPV status is the dominant prognostic factor","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":["rtog-0129","hpv-p16"]},{"group":"history","date":"2010","precision":"year","title":"Sirolimus responses reported in malignant PEComa with TSC loss","note":"Perivascular epithelioid cell tumour (PEComa)","from":"pecoma","refs":["mtor"]},{"group":"history","date":"2010","precision":"year","title":"The first tractable target in squamous lung cancer","note":"Non-small-cell lung cancer. Focal FGFR1 amplification in 22% of squamous cell lung cancers, with selective killing of amplified cell lines by FGFR inhibition.","from":"nsclc","refs":["paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010","fgfr1"]},{"group":"history","date":"2010","precision":"year","title":"The serrated pathway is accepted as a second route to cancer","note":"Colorectal cancer. Sessile serrated lesions and traditional serrated adenomas, with promoter methylation and BRAF or KRAS mutation, account for about 30 percent of colorectal carci...","from":"colorectal","refs":["serrated-pathway","colorectal-polyp-types"]},{"group":"history","date":"2010","precision":"year","title":"TIP neoadjuvant chemotherapy","note":"Penile cancer. Pagliaro and colleagues (JCO 2010) report responses and resectability in bulky nodal disease.","from":"penile","refs":["paclitaxel","cisplatin","ifosfamide"]},{"group":"history","date":"2010","precision":"year","title":"ToGA includes GEJ adenocarcinoma: trastuzumab for HER2-positive disease","note":"Oesophageal cancer","from":"esophageal","refs":["toga","trastuzumab"]},{"group":"history","date":"2010","precision":"year","title":"ToGA: trastuzumab for HER2-positive gastro-oesophageal cancer","note":"Oesophageal and junctional adenocarcinoma","from":"oesophageal-adenocarcinoma","refs":["trastuzumab"]},{"group":"history","date":"2010","precision":"year","title":"ToGA: trastuzumab in HER2+ gastric cancer","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":["trastuzumab"]},{"group":"history","date":"2010","precision":"year","title":"ToGA: trastuzumab plus chemotherapy extends survival in HER2-positive gastric cancer","note":"HER2-positive gastric cancer","from":"gastric-her2-positive","refs":["toga","trastuzumab"]},{"group":"history","date":"2010","precision":"year","title":"ToGA: trastuzumab, the first targeted therapy in gastric cancer","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":["toga","trastuzumab"]},{"group":"history","date":"2010","precision":"year","title":"UKALLR3: mitoxantrone reinduction nearly doubles progression-free survival in relapsed childhood ALL","note":"Relapsed and refractory acute lymphoblastic leukaemia in children","from":"all-paediatric-relapsed","refs":["mitoxantrone"]},{"group":"history","date":"2010","precision":"year","title":"WHO classification separates appendiceal mucinous neoplasms from adenocarcinoma","note":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","from":"appendiceal-adenocarcinoma","refs":[]},{"group":"history","date":"2010","precision":"year","title":"WHO classification separates poorly differentiated neuroendocrine carcinoma from neuroendocrine tumours","note":"Extrapulmonary neuroendocrine carcinoma","from":"extrapulmonary-nec","refs":["net-grade-ki67"]},{"group":"journal","date":"2010","precision":"year","title":"Analytical cellular pathology (Amsterdam) founded","note":"Wiley (formerly Hindawi)","from":"analytical-cellular-pathology","refs":[]},{"group":"journal","date":"2010","precision":"year","title":"Cancer cytopathology founded","note":"Wiley","from":"cancer-cytopathology","refs":[]},{"group":"journal","date":"2010","precision":"year","title":"Clinical lymphoma, myeloma & leukemia founded","note":"Elsevier","from":"clinical-lymphoma-myeloma-and-leukemia","refs":[]},{"group":"journal","date":"2010","precision":"year","title":"Journal of cachexia, sarcopenia and muscle founded","note":"Wiley","from":"journal-of-cachexia-sarcopenia-and-muscle","refs":[]},{"group":"journal","date":"2010","precision":"year","title":"Journal of gastric cancer founded","note":"Korean Gastric Cancer Association","from":"journal-of-gastric-cancer","refs":[]},{"group":"journal","date":"2010","precision":"year","title":"Journal of geriatric oncology founded","note":"Elsevier","from":"journal-of-geriatric-oncology","refs":[]},{"group":"journal","date":"2010","precision":"year","title":"Nature Communications founded","note":"Springer Nature","from":"nature-communications","refs":[]},{"group":"journal","date":"2010","precision":"year","title":"Thoracic cancer founded","note":"Wiley","from":"thoracic-cancer","refs":[]},{"group":"law","date":"2010","precision":"year","title":"Biologics Price Competition and Innovation Act 2010","note":"United States, statute.","from":"bpcia","refs":[]},{"group":"law","date":"2010","precision":"year","title":"Biosimilar","note":"United States, guidance.","from":"biosimilar","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","note":"Sharma SV, Lee DY, Li B, et al. Cell.","from":"paper-sharma-cell","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"A3961: outcome after reduced chemotherapy for intermediate-risk neuroblastoma","note":"Baker DL, Schmidt ML, Cohn SL, et al. New England Journal of Medicine.","from":"paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"ABC-02: cisplatin plus gemcitabine versus gemcitabine alone for biliary tract cancer","note":"Valle J, Wasan H, Palmer DH, et al. New England Journal of Medicine.","from":"paper-abc-02-gemcitabine-cisplatin-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"ALL R3: mitoxantrone versus idarubicin in first relapse of childhood acute lymphoblastic leukaemia","note":"Parker C, Waters R, Leighton C, et al. The Lancet.","from":"paper-all-r3-mitoxantrone-relapsed-childhood-all-parker-lancet-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone re...","note":"Hammond ME, Hayes DF, Dowsett M, et al. Journal of Clinical Oncology.","from":"paper-asco-cap-er-pr-testing-guideline-jco-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","note":"Kwak EL, Bang YJ, Camidge DR, et al. New England Journal of Medicine.","from":"paper-kwak-crizotinib-alk-nsclc-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Angiosarcoma (review)","note":"Young RJ, Brown NJ, Reed MW, et al. The Lancet Oncology.","from":"paper-young-angiosarcoma-review-lancet-oncol-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for high-risk neuroblastoma (COG ANBL0032)","note":"Yu AL, Gilman AL, Ozkaynak MF, et al. New England Journal of Medicine.","from":"paper-yu-anti-gd2-neuroblastoma-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","note":"Wiegand KC, Shah SP, Al-Agha OM, et al. New England Journal of Medicine.","from":"paper-wiegand-arid1a-clear-cell-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","note":"Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Journal of Clinical Oncology.","from":"paper-azacitidine-aml-j-clin-oncol-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Cancer as a metabolic disease","note":"Seyfried TN, Shelton LM. Nutrition & metabolism.","from":"paper-seyfried-nutr-metab-lond","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial","note":"Lu C, Lee JJ, Komaki R, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-lu-j-natl-cancer-inst","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours","note":"Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Journal of Clinical Oncology.","from":"paper-wagner-sirolimus-pecoma-jco-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","note":"Yachida S, Jones S, Bozic I, et al. Nature.","from":"paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial","note":"Rustin GJ, van der Burg ME, Griffin CL, et al. The Lancet.","from":"paper-rustin-lancet","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"ESPAC-3: adjuvant fluorouracil plus folinic acid versus gemcitabine after pancreatic cancer resection","note":"Neoptolemos JP, Stocken DD, Bassi C, et al. JAMA.","from":"paper-espac-3-fluorouracil-vs-gemcitabine-adjuvant-neoptolemos-jama-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","note":"Weiss J, Sos ML, Seidel D, et al. Science Translational Medicine.","from":"paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Frequent mutations of the chromatin remodelling gene ARID1A in ovarian clear cell carcinoma","note":"Jones S, Wang TL, Shih IeM, et al. Science.","from":"paper-jones-arid1a-clear-cell-science-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","note":"Maemondo M, Inoue A, Kobayashi K, et al. New England Journal of Medicine.","from":"paper-egfr-nsclc-n-engl-j-med-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma","note":"Engert A, Plütschow A, Eich HT, et al. New England Journal of Medicine.","from":"paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Grivennikov, Greten and Karin 2010: immunity, inflammation and cancer","note":"Grivennikov SI, Greten FR, Karin M. Cell.","from":"paper-grivennikov-immunity-inflammation-cancer-cell-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","note":"Hodi FS, O'Day SJ, McDermott DF, et al. New England Journal of Medicine.","from":"paper-hodi-ipilimumab-melanoma-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Human papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)","note":"Ang KK, Harris J, Wheeler R, et al. New England Journal of Medicine.","from":"paper-ang-hpv-oropharyngeal-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Imatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)","note":"Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Journal of Clinical Oncology.","from":"paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Integrative genomic profiling of human prostate cancer","note":"Taylor BS, Schultz N, Hieronymus H, et al. Cancer Cell.","from":"paper-taylor-integrative-genomic-profiling-cancer-cell-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Jemal 2010: Cancer statistics, 2010","note":"Jemal A, Siegel R, Xu J, Ward E. CA: A Cancer Journal for Clinicians.","from":"paper-jemal-cancer-statistics-2010-cacancer-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Lemmon and Schlessinger 2010: cell signalling by receptor tyrosine kinases","note":"Lemmon MA, Schlessinger J. Cell.","from":"paper-lemmon-schlessinger-rtk-signalling-cell-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial","note":"Annema JT, van Meerbeeck JP, Rintoul RC, et al. JAMA.","from":"paper-annema-jama","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Multidisciplinary team working in cancer: what is the evidence?","note":"Taylor C, Munro AJ, Glynne-Jones R, et al. BMJ.","from":"paper-taylor-bmj","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study","note":"Issels RD, Lindner LH, Verweij J, et al. The Lancet Oncology.","from":"paper-issels-lancet-oncol","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Neoadjuvant paclitaxel, ifosfamide and cisplatin (TIP) for penile cancer with bulky lymph node metastases","note":"Pagliaro LC, Williams DL, Daliani D, et al. Journal of Clinical Oncology.","from":"paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","note":"Tefferi A. Leukemia.","from":"paper-jak2-myeloproliferative-neoplasms-leukemia-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial","note":"Atkin WS, Edwards R, Kralj-Hans I, et al. The Lancet.","from":"paper-atkin-once-only-flexible-sigmoidoscopy-lancet-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Overdiagnosis in cancer","note":"Welch HG, Black WC. JNCI: Journal of the National Cancer Institute.","from":"paper-welch-j-natl-cancer-inst","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Pancreatic cancer","note":"Hidalgo M. New England Journal of Medicine.","from":"paper-hidalgo-pancreatic-cancer-review-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","note":"Royal RE, Levy C, Turner K, et al. Journal of Immunotherapy.","from":"paper-royal-ipilimumab-pancreatic-j-immunother-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"PORTEC-2: vaginal brachytherapy versus pelvic external beam radiotherapy for high-intermediate-risk endometrial cancer","note":"Nout RA, Smit VT, Putter H, et al. The Lancet.","from":"paper-portec-2-lancet-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","note":"Roth AD, Tejpar S, Delorenzi M, et al. Journal of Clinical Oncology.","from":"paper-kras-colorectal-j-clin-oncol-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers","note":"Domchek SM, Friebel TM, Singer CF, et al. JAMA.","from":"paper-brca-risk-reducing-surgery-jama-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Quality indicators for colonoscopy and the risk of interval cancer","note":"Kaminski MF, Regula J, Kraszewska E, et al. New England Journal of Medicine.","from":"paper-kaminski-adenoma-detection-rate-interval-cancer-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","note":"Bentzen SM, Constine LS, Deasy JO, et al. International Journal of Radiation Oncology, Biology, Physics.","from":"paper-bentzen-int-j-radiat-oncol-biol-phys","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","note":"Badalian-Very G, Vergilio JA, Degar BA, et al. Blood.","from":"paper-badalian-very-braf-mutations-lch-blood-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","note":"Sparano JA, Lee JY, Kaplan LD, et al. Blood.","from":"paper-sparano-blood","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Selective inhibition of BET bromodomains","note":"Filippakopoulos P, Qi J, Picaud S, et al. Nature.","from":"paper-filippakopoulos-nature","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","note":"Kantoff PW, Higano CS, Shore ND, et al. New England Journal of Medicine.","from":"paper-kantoff-n-engl-j-med","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","note":"Barretina J, Taylor BS, Banerji S, et al. Nature Genetics.","from":"paper-barretina-nat-genet","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer","note":"Temel JS, Greer JA, Muzikansky A, et al. New England Journal of Medicine.","from":"paper-temel-early-palliative-care-nejm-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"ToGA (Bang 2010): trastuzumab with chemotherapy for HER2-positive advanced gastric cancer","note":"Bang YJ, Van Cutsem E, Feyereislova A, et al. The Lancet.","from":"paper-toga-trastuzumab-gastric-lancet-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel","note":"de Bono JS, Oudard S, Ozguroglu M, et al. The Lancet.","from":"paper-de-bono-tropic-cabazitaxel-lancet-2010","refs":[]},{"group":"paper","date":"2010","precision":"year","title":"What are the hallmarks of cancer?","note":"Lazebnik Y. Nature Reviews Cancer.","from":"paper-lazebnik-nat-rev-cancer","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo","note":"Journal of Nuclear Medicine","from":"jason-lewis","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection (ESPAC-3)","note":"JAMA","from":"paula-ghaneh","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","note":"Blood","from":"mark-litzow","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","note":"New England Journal of Medicine","from":"alice-yu","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","note":"Genes & Development","from":"adrian-krainer","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia","note":"Nature","from":"marc-raaijmakers","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites","note":"Expert Opinion on Biological Therapy","from":"carsten-bokemeyer","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099","note":"Journal of Clinical Oncology","from":"thomas-lynch","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Childhood cancer trends in a western Canadian province: A population‐based 22‐year retrospective study","note":"Pediatric Blood & Cancer","from":"kent-stobart","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02)","note":"NEJM","from":"juan-valle","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Concurrent radiochemotherapy in advanced hypopharyngeal cancer","note":"Radiat Oncol","from":"igor-stojkovski","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies","note":"Am J Hum Genet","from":"stephen-scherer","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Development of monocytes, macrophages, and dendritic cells","note":"Science","from":"markus-g-manz","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"DNMT3A mutations in acute myeloid leukemia","note":"New England Journal of Medicine","from":"timothy-ley","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients","note":"Journal of Clinical Oncology","from":"dawn-hershman","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Early palliative care for patients with metastatic non-small-cell lung cancer","note":"NEJM","from":"jennifer-temel","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiother...","note":"Annals of Oncology","from":"renaud-de-crevoisier","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study","note":"Oncologist","from":"daniel-serin","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram","note":"Journal of Clinical Oncology","from":"robert-uzzo","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","note":"European Journal of Nuclear Medicine and Molecular Imaging","from":"richard-baum","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX)","note":"Lancet","from":"graham-jackson","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","note":"Nature","from":"tariq-enver","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","note":"The Lancet","from":"shabir-madhi","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-w...","note":"Blood","from":"cheryl-willman","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Improved survival with ipilimumab in patients with metastatic melanoma","note":"New England Journal of Medicine","from":"f-stephen-hodi","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Improving outcomes for patients with diffuse large B-cell lymphoma","note":"CA: a Cancer Journal for Clinicians","from":"christopher-flowers","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype","note":"Journal of Clinical Oncology","from":"charlie-gourley","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Inhibition of mutated, activated BRAF in metastatic melanoma","note":"New England Journal of Medicine","from":"keith-flaherty","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Large animal models of hematopoietic stem cell gene therapy","note":"Gene Therapy","from":"hans-peter-kiem","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label...","note":"Lancet Oncology","from":"vincent-rajkumar","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy","note":"Breast Cancer Research and Treatment","from":"lori-pierce","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Long-term results of hypofractionated radiation therapy for breast cancer","note":"NEJM","from":"timothy-whelan","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Major and minor salivary gland tumors","note":"Critical Reviews in Oncology/Hematology","from":"marco-guzzo","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Management of non-Hodgkin lymphomas arising at extranodal sites","note":"Therapeutische Umschau","from":"franco-cavalli","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Metastatic behavior of breast cancer subtypes","note":"Journal of Clinical Oncology","from":"hagen-kennecke","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL inte...","note":"Blood","from":"christiane-pott","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"mTOR signaling and drug development in cancer","note":"Nature Reviews Clinical Oncology","from":"dancey-janet","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer (EORTC 55971)","note":"NEJM","from":"ignace-vergote","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (ENESTnd)","note":"NEJM","from":"timothy-hughes","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Outcomes of Endoscopic Submucosal Dissection Versus Endoscopic Mucosal Resection in Management of Superficial Squamous Esophageal Neoplasms Outside Japan","note":"Journal of Clinical Gastroenterology","from":"philip-chiu","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials","note":"Journal of Clinical Oncology","from":"katz-artur","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study","note":"International Journal of Cancer","from":"valery-lemmens","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET – Randomised controlled trial","note":"European Journal of Cancer","from":"maurice-van-den-bosch","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Probing the probes: fitness factors for small molecule tools","note":"Chemistry & Biology","from":"paul-workman","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on c...","note":"Lancet Oncology","from":"kathy-albain","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Pr...","note":"JCO","from":"anthony-zietman","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Recent advances in neuroblastoma","note":"NEJM","from":"john-maris","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma (HD10)","note":"NEJM","from":"andreas-engert","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Selenium: a double-edged sword for defense and offence in cancer","note":"Arch Toxicol","from":"miroslav-chovanec","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Stereotactic body radiation therapy for inoperable early stage lung cancer (RTOG 0236)","note":"JAMA","from":"robert-timmerman","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial","note":"Lancet Oncology","from":"cornelis-van-de-velde","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Telomeres and telomerase in cancer","note":"Carcinogenesis","from":"steven-artandi","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)","note":"Lancet","from":"bang-yung-jue","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group (RANO)","note":"JCO","from":"patrick-wen","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2)","note":"Lancet","from":"carien-creutzberg","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised...","note":"Lancet Oncology","from":"john-heymach","refs":[]},{"group":"person-paper","date":"2010","precision":"year","title":"Vitamin D and cancer","note":"Journal of Steroid Biochemistry and Molecular Biology","from":"candace-johnson","refs":[]},{"group":"technology","date":"2010","precision":"year","title":"Adaptive radiotherapy (online replanning)","note":"First use in humans or first approval, as the technology record states it.","from":"adaptive-radiotherapy","refs":[]},{"group":"technology","date":"2010","precision":"year","title":"Dendritic cell vaccines","note":"First use in humans or first approval, as the technology record states it.","from":"dendritic-cell-vaccines","refs":[]},{"group":"technology","date":"2010","precision":"year","title":"Hand-held and point-of-care ultrasound","note":"First use in humans or first approval, as the technology record states it.","from":"hand-held-ultrasound","refs":[]},{"group":"technology","date":"2010","precision":"year","title":"HER2 PET","note":"First use in humans or first approval, as the technology record states it.","from":"her2-pet","refs":[]},{"group":"technology","date":"2010","precision":"year","title":"Percutaneous hepatic perfusion (chemosaturation)","note":"First use in humans or first approval, as the technology record states it.","from":"percutaneous-hepatic-perfusion","refs":[]},{"group":"technology","date":"2010","precision":"year","title":"PET/MRI","note":"First use in humans or first approval, as the technology record states it.","from":"pet-mri","refs":[]},{"group":"technology","date":"2010","precision":"year","title":"Prehabilitation before cancer surgery","note":"First use in humans or first approval, as the technology record states it.","from":"prehabilitation","refs":[]},{"group":"technology","date":"2010","precision":"year","title":"Surface-guided radiotherapy (SGRT)","note":"First use in humans or first approval, as the technology record states it.","from":"surface-guided-radiotherapy","refs":[]},{"group":"trial","date":"2010","precision":"year","title":"A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) reported","from":"nct00106431","refs":["cutaneous-t-cell-lymphoma","romidepsin"]},{"group":"trial","date":"2010","precision":"year","title":"ABC-02 reported","note":"OS 11.7 vs 8.1 months, HR 0.64.","from":"abc-02","refs":["cholangiocarcinoma","gallbladder","biliary-tract-cancer","gemcitabine-cisplatin"]},{"group":"trial","date":"2010","precision":"year","title":"ALL R3 (UKALLR3) reported","note":"Three-year progression-free survival 64.6 percent with mitoxantrone against 35.9 percent with idarubicin, and overall survival 69.0 against 45.2 percent; the randomisation was stop...","from":"ukallr3","refs":["all-paediatric-relapsed","all-leukemia","leukaemia","mitoxantrone"]},{"group":"trial","date":"2010","precision":"year","title":"COG ANBL0032 reported","note":"2-year EFS 66% vs 46%; OS 86% vs 75%.","from":"anbl0032","refs":["neuroblastoma","neuroblastoma-high-risk","dinutuximab","isotretinoin"]},{"group":"trial","date":"2010","precision":"year","title":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing...","from":"nct00099437","refs":["breast-hr-positive","fulvestrant"]},{"group":"trial","date":"2010","precision":"year","title":"DASISION reported","note":"Dasatinib produced higher confirmed complete cytogenetic and major molecular response rates at 12 months than imatinib, with no difference in five-year overall survival.","from":"dasision","refs":["cml-chronic-phase","cml","dasatinib","imatinib"]},{"group":"trial","date":"2010","precision":"year","title":"EORTC 22863 reported","note":"Ten-year overall survival 58.1 against 39.8 percent (hazard ratio 0.60, 95 percent confidence interval 0.45 to 0.80) and prostate cancer mortality 10.3 against 30.4 percent (0.38...","from":"eortc-22863","refs":["prostate","prostate-high-risk","goserelin"]},{"group":"trial","date":"2010","precision":"year","title":"ESPAC-3 reported","note":"Median overall survival 23.0 months with fluorouracil plus folinic acid against 23.6 months with gemcitabine (hazard ratio 0.94, p 0.39); treatment-related serious adverse events 1...","from":"espac-3","refs":["resectable-pdac","pancreatic","ampullary","fluorouracil"]},{"group":"trial","date":"2010","precision":"year","title":"IMPACT (sipuleucel-T) reported","note":"Median overall survival 25.8 against 21.7 months (hazard ratio 0.78, 95 percent confidence interval 0.61 to 0.98, p=0.03) with no difference in time to objective disease progressio...","from":"impact-sipuleucel-t","refs":["prostate","prostate-mcrpc","sipuleucel-t"]},{"group":"trial","date":"2010","precision":"year","title":"NSABP B-32 reported","note":"Eight-year overall survival 90.3 percent with sentinel node biopsy alone against 91.8 percent with added clearance (hazard ratio 1.20, 0.96 to 1.50, p=0.12); regional recurrence 14...","from":"nsabp-b32","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2010","precision":"year","title":"PORTEC-2 reported","note":"Vaginal brachytherapy gave similar vaginal control and survival to external beam radiotherapy with less gastrointestinal toxicity.","from":"portec-2","refs":["endometrial-nsmp","endometrial-pole-ultramutated","endometrial"]},{"group":"trial","date":"2010","precision":"year","title":"RTOG 0129 (HPV analysis) reported","note":"3-year OS 82.4% (HPV+) vs 57.1% (HPV-).","from":"rtog-0129","refs":["head-and-neck","hpv-positive-oropharyngeal-cancer"]},{"group":"trial","date":"2010","precision":"year","title":"ToGA reported","note":"OS 13.8 vs 11.1 months, HR 0.74.","from":"toga","refs":["gastric","gastric-her2-positive","trastuzumab"]},{"group":"trial","date":"2010","precision":"year","title":"TROPIC reported","note":"Median survival 15.1 against 12.7 months (hazard ratio 0.70, 95 percent confidence interval 0.59 to 0.83); grade 3 or higher neutropenia in 82 percent and febrile neutropenia in 8...","from":"tropic","refs":["prostate","prostate-mcrpc","cabazitaxel","mitoxantrone"]},{"group":"trial","date":"2010","precision":"year","title":"UK Flexible Sigmoidoscopy Screening Trial reported","note":"Colorectal cancer incidence 23 percent lower and mortality 31 percent lower in those invited to a single flexible sigmoidoscopy (33 percent and 43 percent among attenders); the 17-...","from":"ukfss","refs":["colorectal"]},{"group":"regulatory","date":"2010-06-21","precision":"day","title":"Gemtuzumab ozogamicin: withdrawal (US)","note":"Voluntary withdrawal after confirmatory trial showed no benefit and excess deaths","from":"gemtuzumab-ozogamicin","refs":[]},{"group":"regulatory","date":"2010-10-20","precision":"day","title":"Trastuzumab: approval (US)","note":"HER2+ metastatic gastric cancer (ToGA)","from":"trastuzumab","refs":[]}]},"route":"/years/2010/","neighbours":{"year":[{"id":"2009","kind":"year","name":"2009 in oncology","route":"/years/2009/"},{"id":"2011","kind":"year","name":"2011 in oncology","route":"/years/2011/"}]}}